> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Guidance on Paliperidone Palmitate
- URL: https://www.fdaweb.com/guidance-on-paliperidone-palmitate/
- Published: 2016-01-04T12:00:00.000Z
- Updated: 2026-09-15T02:24:22.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5134314

*Federal Register* Notice: FDA is making available a revised [draft guidance](http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm270384.pdf?ref=fdaweb.com) for industry entitled *Draft Guidance on Paliperidone Palmitate*. The recommendations provide specific guidance on the design of bioequivalence studies to support ANDAs for paliperidone palmitate extended-release injectable suspension. To view this notice, click [here.](https://www.gpo.gov/fdsys/pkg/FR-2015-12-29/pdf/2015-32723.pdf?ref=fdaweb.com)